AzTrials
AzTrials

Urinary InfectionAblaJNCT04913753

Relevance of the Urine Bacterial Culture Performed Before Double J Ablation for Post-operative Urinary Tract Infection Prevention

A study testing CBEU and No CBEU in people with Urinary Infection, run by University Hospital, Tours at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The value of cytobacteriological examination of urine (CBEU) before double J catheter removal has not been demonstrated. The aim of this study is to define the interest of this CBEU. Read more about this study

Who is it for?
Ages 18 to 100 years
Conditions the study is for
Urinary Infection
What is being tested?
CBEU and No CBEU
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
2,200 participants
Where
1 siteFrance
Study dates
10 Jun 2021to 3 Dec 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 100 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Participant ≥ 18 years of age
  • Scheduled to have a double J catheter ablation
  • Participants covered by or entitled to social security
  • Written informed consent obtained from the participant
  • Ability for participant to comply with the requirements of the study

Who cannot join

  • Patients already receiving antibiotics other than urological reasons and transplanted patients
  • Study interventions contraindications
  • Pregnancy, breastfeeding
  • Patient under tutorship or curators
  • Deprivation of liberty

Trial locations and contacts

1 site in 1 country.

France1 site
  • BRUYERE

    Tours, 37044

Other trials in France

About this study

The value of cytobacteriological examination of urine (CBEU) before double J catheter removal has not been demonstrated. The aim of this study is to define the interest of this CBEU.

Read the detailed description

Double J stents are ureteral catheters that allow urine to flow from the kidney without difficulty. These catheters protect the ureterovesical anastomosis of a renal transplant or reduce the postoperative oedema, for example after stone removal by ureteroscopy. These catheters are removed in an outpatient setting under local anaesthesia. Post ablation infections of double J catheters have been poorly studied but their incidence varied according to the populations and the definition used (10 to 54% for colonization, 1 to 10% for symptomatic infection). The national and international guidelines advocate a routine urine bacterial culture (UBC) before double J catheter removal as the procedure is in contact with urine; but there is no evidence of its interest. In case of positivity of this culture, it is recommended to delay the intervention or, what is more often chosen, to treat with antibiotic to cover the procedure. Investigators can thus ask 2 questions: is it rightful to withdraw a double J removal while the UBC is falsely negative and in case of a positive bacterial culture is there an increased risk of post-ablation infection?

Being tested
CBEU, No CBEU
Medical subject headings
Urinary Tract Infections

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CBEUProcedure or surgery

    Patients in the control group will have bacterial culture and double J removal will be performed as usual. .

  • No CBEUProcedure or surgery

    Patients in the experimental group will have bacterial culture and double J removal will be performed as usual. .

Study groups in NCT04913753
Study groupRoleWhat they receive
No systematic CBEUExperimentalPatients will not have bacterial culture performed before double J removal.
Receives: Procedure: No CBEU
Systematic CBEUActive comparatorPatients will have a systematic urine culture performed before double J removal.
Receives: Procedure: CBEU

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of infection

    Incidence over a month period of post-ablation symptomatic urinary infection defined by the presence of symptoms validated by an adjudication committee (urine burning, fever, urgencies… associated to a significant bacteriuria) - each patient will be contacted by phone at month 1 (± 5 days) and will be asked to contact us in case of suspicion of urinary infection.

    Measured: 1 month post double J removal

Secondary outcomes (7)
  1. Incidence of bacteriuria measured by CBEU

    Incidence of post-ablation bacteriuria (urosepsis and antibiotic use) in different groups of patients (reason of the stent, duration of the insertion, previous infection, immunodepression….) in the 1 month post-ablation period

    Measured: 1 month post double J removal

  2. Description of the resistance type of pre-operative distribution of bacteriuria by CBEU

    Epidemiology of the resistance type of pre-operative bacteriuria

    Measured: 10 days to 4 days before double J removal

  3. Description of the pre-operative distribution of bacteriuria by CBEU

    Epidemiology of pre-operative bacteriuria

    Measured: 10 days to 4 days before double J removal

  4. Description of the resistance type of post operative distribution of bacteriuria by CBEU

    Epidemiology of the resistance type of post-ablation bacteriuria

    Measured: 1 month after double J removal

  5. Description of the post operative distribution of bacteriuria by CBEU

    Epidemiology of post-ablation bacteriuria

    Measured: 1 month after double J removal

  6. Composition of microbiome by bacterial urinary analysis

    Comparison of the pre-operative urinary microbiome to the post-ablation urinary microbiome in patient with post-ablation infection.

    Measured: 1 month post double J removal

  7. Health-economic outcome

    Proportion of incremental costs-effects pairs that lies in the non-inferiority area, for various values of economic non-inferiority

    Measured: 1 month post double J removal

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Jun 2021
  2. Study start10 Jun 2021
  3. Primary completion3 Dec 2025
  4. Study completion3 Dec 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
2,200 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04913753
Sponsor's protocol ID
DR200086 - ABLAJ
Acronym
AblaJ
Status last verified
Dec 2025
First submitted
19 May 2021
Last updated
12 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing CBEU and No CBEU in people with Urinary Infection, run by University Hospital, Tours at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of infection (time frame: 1 month post double J removal). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in